Pasar al contenido principal

ENCAPSULACIÓN DE CÉLULAS CART EN SISTEMAS POROSOS NANOESTRUCTURADOS BIOACTIVOS PARA SU LIBERACIÓN DIRIGIDA EN TUMORES SOLIDOS

PLEC2022-009217

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i en Líneas Estratégicas
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDADE DE SANTIAGO DE COMPOSTELA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Active R-RAS2/TC21 prevents cell cycle arrest and morphological alterations in mouse embryonic fibroblasts lacking RAS proteins.

  • Fernández-Pisonero, Isabel
  • Lorenzo-Martín, L Francisco
  • Drosten, Mattias
  • Santos, Eugenio
  • Barbacid, Mariano
  • Alarcón, Balbino
  • Bustelo, Xosé R
R-RAS2/TC21, a member of the R-RAS subfamily of GTP-binding proteins, shares structural and signaling properties with the RAS subfamily proteins H-, K-, and N-RAS. However, little information is available regarding its role in normal cells and the level of functional redundancy with R-RAS and classical RAS proteins. In this work, we used loss and gain-of-function approaches to assess these issues in mouse embryonic fibroblasts (MEFs). Using primary MEFs from Rras2, Rras or Rras; Rras2 embryos, we show here that endogenous R-RAS2/TC21 is required for activation of the phosphatidylinositol 3 kinase (PI3K)-AKT axis, the proliferation, and the adhesion properties of these cells. Endogenous R-RAS does not influence any of these cell parameters. We also show that the depletion of R-RAS2/TC21 worsens the proliferative and morphological defects elicited by the combined loss of H-, K- and N-RAS proteins in MEFs. Conversely, the ectopic expression of an active version of R-RAS2/TC21, but not of R-RAS, overcomes such defects. This rescue activity involves the inhibition of the tumor suppressor TP53 and is PI3K-, mTORC-, and MEK/ERK-dependent. These results indicate that R-RAS2/TC21, R-RAS, and RAS subfamily GTPases play different roles in MEFs. They also show that R-RAS2 provides subsidiary signals that are essential for the short-term proliferation and long-term viability of MEFs lacking RAS signaling.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Predicting the Dominant Role of Dense Aggregates in Magnetic Hyperthermia via Intracellular-Mimetic Nanoparticle Models

  • García Acevedo, Pelayo
  • Paz Castro, Alba
  • Estébanez Pisonero del Pozo, Jorge
  • Piñeiro Redondo, Yolanda
  • Rivas Rey, José
Dense aggregation of magnetic nanoparticles (MNPs) in cellular environments is a major contributor to reduced magnetic hyperthermia (MH) efficiency; however, in situ magnetic characterization remains challenging, necessitating reliable extracellular models to predict such behavior. In this study, soft and dense aggregates (≈200 nm) are engineered using 10 nm iron oxide MNPs, encapsulated in polymeric (soft) or inorganic (dense) shells, with morphological features and strong magnetic dipolar interactions confirming their similarity to nanoparticle assemblies found in living cells. Unlike previous studies that induced aggregation by modifying the surrounding medium, the approach enables controlled, invariant aggregation states, allowing systematic evaluation of the transition from soft to dense aggregation under both aqueous and high-viscosity, cell-mimicking conditions. Results demonstrate that dense aggregation leads to a >20% reduction in specific absorption rate (SAR), primarily due to decreased remanent magnetization (MR), highlighting the critical role of aggregate structure. Viscosity is found to have a non-negligible effect once MNPs are aggregated, suggesting dominant Néel relaxation modulated by dipolar interactions. A strong SAR–MR correlation is observed, while SAR–coercivity (HC) dependence is disrupted by aggregation. These findings offer new insights for optimizing MH efficiency and guiding the design of magnetic nanoactuators for MH therapy.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Sos1 ablation alters focal adhesion dynamics and increases Mmp2/9-dependent gelatinase activity in primary mouse embryonic fibroblasts

  • Liceras-Boillos, Pilar
  • García-Navas, Rósula
  • Llorente-González, Clara
  • Lorenzo-Martín, L. Francisco
  • Luna Ramírez, Luis
  • Fuentes Mateos, Rocío
  • Calzada, Nuria
  • Vega, Francisco M.
  • Holt, Mark R.
  • Ridley, Anne J.
  • Bustelo, Xosé R.
  • Vicente-Manzanares, Miguel
  • Santos de Dios, Eugenio
  • Baltanás, Fernando C.
[Background] Sos1 and Sos2 are guanine-nucleotide exchange factors for Ras and Rac small GTPases, which are involved in a wide range of cellular responses including proliferation and migration. We have previously shown that Sos1 and Sos2 have different effects on cell migration, but the underlying mechanisms are not clear., [Methods] Using a 4-hydroxytamoxifen-inducible conditional Sos1KO mutation, here we evaluated the functional specificity or redundancy of Sos1 and Sos2 regarding the control of cell migration and dynamics of focal adhesions (FAs) in primary mouse embryonic fibroblasts (MEFs)., [Results] Functional analysis of the transcriptome of primary Sos1/2WT, Sos1KO, Sos2KO and Sos1/2DKO-MEFs revealed a specific, dominant role of Sos1 over Sos2 in transcriptional regulation. Sos1KO MEFs had an increased number and stability of focal adhesions (FAs) and curbed protrusion and spreading. Conversely, Sos2KO MEFs displayed unstable FAs with increased protrusion. Interestingly, Sos1, but not Sos2, ablation reduced the levels of GTP-bound Rac at the leading edge. In 3D, however, only Sos1/2KO MEFs showed increased invasion and matrix degradative capacity, which correlated with increased expression of the Mmp2 and Mmp9 gelatinases. Moreover, increased matrix degradation in Sos1/2KO MEFs was abrogated by treatment with Mmp2/9 inhibitors., [Conclusions] Our data demonstrate that Sos1 and Sos2 have different functions in FAs distribution and dynamics in 2D whereas in 3D they act together to regulate invasion and unveil a previously undescribed mechanistic connection between Sos1/2 and the regulation of Mmp2/9 expression in primary MEFs., This work was funded by grants ISCIII-MCUI (FIS PI19/00934), JCyL (SA264P18-UIC 076), Areces Foundation (CIVP19A5942) and ISCIII-CIBERONC (group CB16/12/00352) to E.S; Solórzano-Barruso Foundation (FS/32-2020), Ministerio de Ciencia e Innovación (MICIU/AEI/https://doi.org/10.13039/501100011033/, as part of I + D + i Project “PID2022-136409OB-I00” and MICIU/AEI/https://doi.org/10.13039/501100011033/ and NextGenerationEU/PRTR, as part of I + D + i Project “CNS2022-135292), Eugenio Rodriguez Pascual Foundation and Asociación Inés de Pablo Llorens-GETTHI to F.C.B; Federación Española de Enfermedades Raras (AI-2023-015) to F.M.V; Ministerio de Ciencia e Innovación (PID2020-116232RB-I00) and ECRIN-M3 from AECC/AIRC/CRUK to M.V-M; Cancer Research UK (C6620/A15961) to A.J.R. The X.R.B.’s project leading to these results has received funding from the AECC (GC16173472GARC), the Castilla-León government (CSI018P23), grants funded by MCIN/AEI/https://doi.org/10.13039/501100011033/ plus the European Research Development Fund «A way of making Europe» of the European Union (PID2021-122666OB-I00, PDC2022-133027-I00, PLEC2022-009217), «la Caixa» Banking Foundation (HR20-00164), and the «Escalera de Excelencia» of the Education Ministry of the Castilla y León autonomous government plus the European Research Development Fund (CLU-2023-2-01). This research was co-financed by FEDER funds. These CIC groups are supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia of Castilla y León autonomous government (CLC-2017-01) and AECC Excellence program Stop RAS Cancers (EPAEC222641CICS)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Active R-RAS2/TC21 prevents cell cycle arrest and morphological alterations in mouse embryonic fibroblasts lacking RAS proteins

  • Fernández-Pisonero, Isabel
  • Lorenzo-Martín, L. Francisco
  • Drosten, Matthias
  • Santos de Dios, Eugenio
  • Barbacid, Mariano
  • Alarcón, Balbino
  • Bustelo, Xosé R.
R-RAS2/TC21, a member of the R-RAS subfamily of GTP-binding proteins, shares structural and signaling properties with the RAS subfamily proteins H-, K-, and N-RAS. However, little information is available regarding its role in normal cells and the level of functional redundancy with R-RAS and classical RAS proteins. In this work, we used loss and gain-of-function approaches to assess these issues in mouse embryonic fibroblasts (MEFs). Using primary MEFs from Rras2–/–, Rras–/– or Rras–/–; Rras2–/– embryos, we show here that endogenous R-RAS2/TC21 is required for activation of the phosphatidylinositol 3 kinase (PI3K)–AKT axis, the proliferation, and the adhesion properties of these cells. Endogenous R-RAS does not influence any of these cell parameters. We also show that the depletion of R-RAS2/TC21 worsens the proliferative and morphological defects elicited by the combined loss of H-, K- and N-RAS proteins in MEFs. Conversely, the ectopic expression of an active version of R-RAS2/TC21, but not of R-RAS, overcomes such defects. This rescue activity involves the inhibition of the tumor suppressor TP53 and is PI3K-, mTORC-, and MEK/ERK-dependent. These results indicate that R-RAS2/TC21, R-RAS, and RAS subfamily GTPases play different roles in MEFs. They also show that R-RAS2 provides subsidiary signals that are essential for the short-term proliferation and long-term viability of MEFs lacking RAS signaling., The XRB’s project leading to these results has received funding from the Spanish Association against Cancer (GC16173472GARC), the Castilla-León government (CSI018P23), grants funded by MCIN/AEI/10.13039/501100011033/ plus the European Research Development Fund «A way of making Europe» of the European Union (PID2021-122666OB-I00, PDC2022-133027-I00, PLEC2022-009217), «la Caixa» Banking Foundation (HR20-00164), the «Programa Excelencia» of the Fundación Científica AECC 2022 (EPAEC222641CICS), and the «Escalera de Excelencia» of the Education Ministry of the Castilla y León autonomous government plus the European Research Development Fund (CLU-2023-2-01)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The mevalonate pathway contributes to breast primary tumorigenesis and lung metastasis

  • Conde, Javier
  • Fernández-Pisonero, Isabel
  • Lorenzo-Martín, L. Francisco
  • García-Gómez, Rocío
  • Berta, Casar
  • Crespo, Piero
  • Bustelo, Xosé R.
The mevalonate pathway plays an important role in breast cancer and other tumor types. However, many issues remain obscure as yet regarding its mechanism of regulation and action. In the present study, we report that the expression of mevalonate pathway enzymes is mediated by the RHO guanosine nucleotide exchange factors VAV2 and VAV3 in a RAC1- and sterol regulatory element-binding factor (SREBF)-dependent manner in breast cancer cells. Furthermore, in vivo tumorigenesis experiments indicated that the two most upstream steps of this metabolic pathway [3-hydroxy-3-methylglutaryl-coenzyme A synthase 1 (HMGCS1) and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)] are important for primary tumorigenesis, angiogenesis, and cell survival in breast cancer cells. HMGCR, but not HMGCS1, is also important for the extravasation and subsequent fitness of breast cancer cells in the lung parenchyma. Genome-wide expression analyses revealed that HMGCR influences the expression of gene signatures linked to proliferation, metabolism, and immune responses. The HMGCR-regulated gene signature predicts long-term tumor recurrence but not metastasis in cohorts of nonsegregated and chemotherapy-resistant breast cancer patients. These results reveal a hitherto unknown, VAV-catalysis-dependent mechanism involved in the regulation of the mevalonate pathway in breast cancer cells. They also identify specific mevalonate-pathway-dependent processes that contribute to the malignant features of breast cancer cells., XRB's project leading to these results has received funding from grants cofounded by MCIN/AEI/10.13039/501100011033/ plus the European Research Development Fund “A way of making Europe” of the European Union (PID2021-122666OB-I00, PDC2022-133027-I00, PLEC2022-009217), “la Caixa” Banking Foundation (HR20-00164), the Castilla-León government (CSI018P23), and the Programa Excelencia of the Fundación Científica AECC 2022 (EPAEC222641CICS). The authors' institution was supported by the Programas de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia of the Castilla-León government (CLC-2017-01 and CL-EI-2021-02) that were both cofounded by the European Research Development Fund. JC contract was supported by a Sara Borrel contract from the Spanish Carlos III Health Institute. LFL-M contract was mostly supported by funding from the Spanish Ministry of Education, Culture and Sports (FPU13/02923) and, subsequently, by the CLC-2017-01 grant., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pan-cancer analyses identify oncogenic drivers, expression signatures, and therapeutic vulnerabilities in RHO GTPase pathway genes

  • Fernández, Rubén
  • Lorenzo-Martín, L. Francisco
  • Quesada, Víctor
  • Bustelo, Xosé R.
RHO family GTPases are key regulators of cancer-related processes such as cytoskeletal dynamics and cell migration, proliferation, and survival. Despite this, a comprehensive understanding of RHO signaling alterations across tumors is still lacking. In this study, we present a pan-cancer analysis of 484 genes encoding RHO GTPases, regulators, proximal effectors, distal downstream signaling elements, and components of their proximal interactomes using data from over 10,000 tumor samples and 33 tumor types present in The Cancer Genome Atlas (TCGA). In addition, we have utilized available data from genome-wide functional dependency screens performed in more than 1,000 gene-edited cancer cell lines. This study has uncovered positively selected mutations in both well-known and previously uncharacterized RHO pathway genes. Transcriptomic profiling reveals widespread and tumor-specific differential expression patterns, with some of them correlating with copy number changes. Interestingly, certain regulators exhibit consistent expression profiles across tumors opposite to those predicted from their canonical roles. Co-expression and gene set enrichment analyses highlight coordinated transcriptional programs involving some RHO GTPase pathway genes and their linkage to key cancer hallmarks, including extracellular matrix reorganization, cell motility, cell cycle progression, cell survival, and immune modulation. Functional screens further identify context-specific dependencies on several deregulated RHO GTPase pathway genes. Altogether, this study provides a comprehensive map of RHO GTPase pathway alterations in cancer and identifies new oncogenic drivers, expression-based signatures, and therapeutic vulnerabilities that could guide future mechanistic and translational research in this area., The XRB’s project leading to these results has received funding from the Spanish Association against Cancer (GC16173472GARC), the Castilla-León government (CSI018P23), grants funded by MCIN/AEI/10.13039/501100011033/plus the European Research Development Fund «A way of making Europe» of the European Union (PLEC2022-009217, PID2024-156980OB-I00), and «la Caixa» Banking Foundation (HR20-00164). In addition, the Centro de Investigación del Cáncer (CIC) of Salamanca received funding from the «Programa Excelencia» of the Fundación Científica AECC 2022 (EPAEC222641CICS), the «Escalera de Excelencia» of the Education Ministry of the Castilla y León autonomous government plus the European Research Development Fund (CLU-2023-2-01), and the CSIC-MaX Program., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Ribosomal protein deficiencies linked to Diamond-Blackfan anemia induce distinctive alterations of ATF4 expression

  • Lorenzo-Martín, L. Francisco
  • Robles-Valero, Javier
  • Ramírez-Cota, Rosa
  • Gaspar, Sonia G.
  • Fuentes, Pedro
  • Gentilella, Antonio
  • Bustelo, Xosé R.
  • Dosil, Mercedes
Ribosomal protein haploinsufficiency causes Diamond-Blackfan anemia (DBA) and other ribosomopathies. DBA has been linked to p53 activation and reduced GATA1 expression, but these mechanisms do not fully explain the disease. This study unveils that deficiencies in small (RPS) or large (RPL) ribosomal subunit proteins cause a p53-independent loss of ATF4, a master regulator of stress responses and erythropoiesis, by reducing the pool of actively translating ATF4 mRNAs. This defect is more pronounced in RPS deficiencies because the loss of 40S, but not 60S, subunits cause a destabilization of ATF4 transcripts. ATF4 downregulation occurs in early hematopoietic progenitors and correlates with the severity of erythroid differentiation defects in patients with DBA. It is also linked to the de-repression of fetal hemoglobin in erythroid cells, a frequent feature in patients with DBA. Our findings indicate that impaired ATF4 expression might be a primary contributor to DBA and explain the aggravated erythroid failure of RPS-mutant patients., M.D. research has been financed by grants BFU2017-88192-P and PID2020-118378GB-I00, both of them co-funded by MCIN/AEI/10.13039/501100011033/ plus the European Research Development Fund “A way of making Europe” of the European Union. X.R.B. has received funding from the Castilla-León government (CSI145P20, CSI018P23), grants co-funded by MCIN/AEI/10.13039/501100011033/ plus the European Research Development Fund “A way of making Europe” of the European Union (PID2021-122666OB-I00, PDC2022-133027-I00, PLEC2022-009217), “la Caixa” Banking Foundation (HR20-00164), and the Programa Excelencia of the Fundación Científica AECC 2022 (EPAEC222641CICS). J.R.-V. received funding from the Carlos III Health Institute (PI20/01724). M.D. and X.R.B. center was supported by the Programas de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia of the Castilla-León government (CLC-2017-01 and CL-EI-2021-02) that were both co-funded by the European Research Development Fund., Peer reviewed